Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 2Hematologic Diseases 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 33Pemetrexed 25Cisplatin 23Paclitaxel 20Radiotherapy 16Docetaxel 16Gemcitabine 15durvalumab 14Radiosurgery 14pembrolizumab 13Nivolumab 13Erlotinib Hydrochloride 10Taxes 8atezolizumab 7Magnetic Resonance Spectroscopy 7Drug Therapy 6Cyclophosphamide 6Bevacizumab 6Platinum 5Gefitinib 5130-nm albumin-bound paclitaxel 5Etoposide 4Biopsy 4Albumin-Bound Paclitaxel 41,2-diaminocyclohexaneplatinum II citrate 4spartalizumab 3sotorasib 3poly ICLC 3capmatinib 3Surveys and Questionnaires 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Non-Small-Cell Lung × INCB039110 × Clear all
NCT02355431 2019-03-08

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Incyte Corporation

Phase 2 Withdrawn
Other hematologic neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡